Strategic Partnerships ProBioGen regularly engages in collaborations with industry players such as ModeX Therapeutics, Polpharma Biologics, and Mapp Biopharmaceutical to advance biopharmaceutical development. This indicates a receptive audience for strategic CDMO partnerships and joint development programs that you can target with tailored collaboration proposals.

Platform Capabilities Recent enhancements include a predictive platform for clone selection and proprietary technologies like DirectedLuck transposase and GlymaxX to boost ADCC. These differentiators can be positioned to attract biotech and pharma clients seeking faster, higher quality cell line development and engineered antibody products.

Vaccine and Vectors Launch of an avian designer cell line for poxvirus vaccines signals capability in vaccine manufacturing and viral vectors. This opens outreach to vaccine developers and carriers of infectious disease programs looking for scalable, GMP-compliant manufacturing and analytics.

Global and Local Footprint With three manufacturing lines in Berlin and substantial experience since 1994, ProBioGen presents a robust European CDMO footprint. This can be leveraged to target European biotechs seeking nearshore manufacturing, storage, and regulatory alignment within the EU framework.

Financial and Scale Estimated revenue in the lower double-digit millions and a skilled team of 51–200 employees indicate a mid-market CDMO with flexibility for mid-scale projects, fast cycle times, and customized services. This positions ProBioGen as a potential partner for mid-sized programs that require hands-on collaboration and adaptable manufacturing scales.